Metropolitan Life Insurance Co. NY Sells 1,374 Shares of Illumina, Inc. (ILMN)

Metropolitan Life Insurance Co. NY cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 78,155 shares of the life sciences company’s stock after selling 1,374 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Illumina were worth $13,336,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ILMN. Advocacy Wealth Management Services LLC purchased a new stake in shares of Illumina during the first quarter worth approximately $102,000. Advisory Services Network LLC purchased a new stake in shares of Illumina during the first quarter worth approximately $117,000. Gemmer Asset Management LLC boosted its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the period. Probity Advisors Inc. purchased a new stake in shares of Illumina during the first quarter worth approximately $204,000. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in shares of Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 96.85% of the company’s stock.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.55% during trading on Friday, reaching $184.00. 495,003 shares of the company traded hands. The firm’s 50 day moving average is $178.46 and its 200-day moving average is $163.46. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $189.48. The stock has a market capitalization of $26.86 billion, a P/E ratio of 37.24 and a beta of 0.76.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The firm had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.71 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post $3.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Sells 1,374 Shares of Illumina, Inc. (ILMN)” was first published by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.mideasttime.com/metropolitan-life-insurance-co-ny-sells-1374-shares-of-illumina-inc-ilmn/1805897.html.

A number of analysts have commented on the stock. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research report on Wednesday. Morgan Stanley reaffirmed an “underweight” rating and set a $115.00 price target (up previously from $108.00) on shares of Illumina in a research report on Monday, May 15th. Deutsche Bank AG reaffirmed a “hold” rating and set a $175.00 price target (up previously from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price target on shares of Illumina in a research report on Wednesday, April 26th. Finally, Cantor Fitzgerald upped their price target on shares of Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a research report on Wednesday, April 26th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $165.02.

In related news, SVP Charles Dadswell sold 1,609 shares of the stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the transaction, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $172.72, for a total transaction of $518,160.00. Following the transaction, the director now owns 18,704 shares in the company, valued at approximately $3,230,554.88. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,785 shares of company stock worth $17,041,458. 1.60% of the stock is owned by insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ILMN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.